Skip to search formSkip to main contentSkip to account menu

crizotinib

Known as: (R)-Crizotinib, 2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-, (R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine 
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth… 
National Institutes of Health

Related topics

Related topics

11 relations
ALK protein, humanNCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionReceptor Tyrosine Kinase Inhibitors [MoA]

Narrower (2)

PF-2341066Xalkori

Broader (3)

Protein Kinase InhibitorsPyrazolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.
Background Crizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with anaplastic lymphoma kinase… 
Review
2017
Review
2017
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
LBA9008Background: Alectinib, a TKI targeting ALK, has shown robust efficacy in crizotinib-naive/resistant ALK+ NSCLC. J-ALEX… 
2016
2016
Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
A study reported in this issue of The Oncologist examined the utility of next-generation sequencing (NGS) in detecting ALK… 
2016
2016
Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
Brain metastasis in non small cell lung cancer (NSCLC) patients is often considered as a terminal stage of advanced disease… 
2015
2015
Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.
8063 Background: Both intrinsic and acquired resistance mechanisms to ALK inhibitors have been observed in ALK rearranged (ALK… 
2014
2014
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Case Report A67-year-oldwhitewomanwhohadneversmokedandwasasymptomatic (Eastern Cooperative Oncology Group performance group… 
2014
2014
Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia
Shi L , Sun X , Zhang J , Zhao C , Li H , Liu Z , et al . Gab2 [1] expression in glioma and its implications for tumor invasion… 
2012
2012
Drug approvals 2011: focus on companion diagnostics.
.S. Food and Drug Administration officials and cancer care advocacy groups are hailing 2011 as a milestone year in the… 
2011
2011
Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.
e13065 Background: Crizotinib is a selective, ATP-competitive, small molecule inhibitor of the ALK and MET/HGF receptor tyrosine… 
Review
2011
Review
2011
Target Therapies in Lung Cancer
Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)